SESSION I: FIXED VS CONTINUOUS TREATMENTS IN HIGH-RISK PATIENTS

First-line therapy for adult and elderly patients
L. Laurenti (Roma)
MRD in the targeted therapy era: a necessary question?
A. Tedeschi (Milano)
SESSION II: NEW SCENARIOS IN CLL

Evolving therapeutic strategies in R/R CLL
M. Coscia (Varese)
Management of long-term survivors in the era of targeted therapy
L. Mettivier (Salerno)
Novel prognostic biomarkers and risk stratification systems
V. Giudice (Salerno)
Keynote Lecture

Current and emerging therapies in Mantle Cell Lymphoma
A. Pinto (Napoli) - NON AUTORIZZATA
SESSION IV: NEW PERSPECTIVES IN R/R DLBCL

Emerging drugs in R/R DLBCL
M. Martelli (Roma)
CAR-T cell therapy: what is the best timing?
M. Martino (Reggio Calabria)
SESSION V: CONTROVERSIES IN R/R FL

CAR-T cell before new drugs: No
M. Gentile (Cosenza)
CAR-T cell before new drugs: Yes
F. Frigeri (Caserta)
SESSION VI: LYMPHOMAS QUESTIONS and ANSWERS

SESSION VI: LYMPHOMAS QUESTIONS and ANSWERS
L. Pezzullo (Salerno)
Privacy Policy | Cookie Policy